

# **POSTER PRESENTATION**

**Open Access** 

# Safety, tolerability and feasibility of adenosine stress CMR in high-risk patients

Amardeep Ghosh Dastidar\*, Alexander Carpenter, Catherine R Wilson, Nauman Ahmed, Chris B Lawton, Mark Hamilton, Chiara Bucciarelli-Ducci

From 18th Annual SCMR Scientific Sessions Nice, France. 4-7 February 2015

### **Background**

Adenosine stress cardiovascular magnetic resonance (CMR) provides effective cardiac prognostication in patients with suspected coronary artery disease. However its use has been limited in high-risk patients and some reservations exist about offering adenosine stress CMR in patients with significant aortic stenosis, asthma, severe left ventricular (LV) systolic dysfunction, significant left main stem (LMS) disease and age >80years.

#### **Aims**

To determine the safety, tolerability and feasibility of stress CMR, in the diagnosis of inducible myocardial ischaemia in high-risk individuals as compared to non-high risk.

#### **Methods**

From April 2013-February 2014, 542 consecutive adenosine stress-CMR examinations were performed. Cardiovascular and symptomatic response to adenosine stress was recorded in every patient. The CMR protocol included cine (long and short axis), stress and rest first-pass perfusion imaging, and late gadolinium enhancement (LGE) imaging. Patients were classed as high-risk if any of the following criteria were fulfilled: age >80yrs, asthma or chronic obstructive pulmonary disease (COPD), significant left main stem stenosis and moderate-severe or severe aortic stenosis or severe LV systolic dysfunction (ejection fraction <40%). Comparisons were made using the Fisher exact test for binary variables.

#### Results

542 consecutive stress-CMR were included in the analysis (mean age 64 years and 71% males), out of which 99 patients (18%) met the criteria for high-risk. Overall,

the complete stress-CMR protocol was successfully performed in 93% of patients. The high-risk group had a drop out rate of 1% compared to a rate of 8% for the non-high risk group (p=0.01). Adequate stress response (symptomatic and/or cardiovascular) was achieved in 98% of high-risk and 99% of non-high risk (p=0.62). 74% of high-risk patients received incremental increase in adenosine dose. Overall, no serious adverse events were noted. When compared to non-high risk, the high-risk group more commonly presented with inducible perfusion defects (63% vs 39%, p=0.0003) and LGE (74% vs 50%, p=<0.0001) (Table 1).

## **Conclusions**

Adenosine stress-CMR is a safe, well-tolerated and feasible investigational modality in high-risk individuals (moderate/severe aortic stenosis, significant LMS stenosis, severe LV systolic dysfunction, asthma/COPD or age >80) with suspected ischaemic heart disease. The incidence of myocardial ischemia or LGE is significantly higher in the high-risk group.

# **Funding**

This study was funded by the National Institute for Health Research Biomedical Research Unit in Cardiovascular

Table 1

	Total (542)	High-risk (99)	Non-high risk (443)	P-value
Male (%)	387 (71.4)	70 (70.7)	317 (71.6)	0.90
Stress response	535	97	438	0.62
Drop out	35	1	34	0.01
Ischaemia	234	62	172	0.0003
LGE	295	73	222	<0.0001

NIHR Cardiovascular Biomedical Research Unit, Bristol Heart Institute, Bristol, UK



Dastidar *et al. Journal of Cardiovascular Magnetic Resonance* 2015, **17**(Suppl 1):P124 http://www.jcmr-online.com/content/17/S1/P124

Disease at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol.

Published: 3 February 2015

doi:10.1186/1532-429X-17-S1-P124

Cite this article as: Dastidar et al.: Safety, tolerability and feasibility of adenosine stress CMR in high-risk patients. Journal of Cardiovascular Magnetic Resonance 2015 17(Suppl 1):P124.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

